SynthesisThe European respiratory journal2023
Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis.
Open access · bronzeAbstract readSystematic ReviewMeta-Analysis
In one paragraph
Synthesis in The European respiratory journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 3 pooled it
2.6field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 30 citations in OpenAlex.
- Preclinical studies of conditioned medium of hypoxic-preconditioned mesenchymal stem cell/hypMSC-CM for ischemic stroke: A systematic review.Open veterinary journal · 2026Pooled it
- Pharmacogenomic insights into tuberculosis treatment shows the NAT2 genetic variants linked to hepatotoxicity risk: a systematic review and meta-analysis.BMC genomic data · 2024Pooled it
- Can we Predict Drug Excretion into Saliva? A Systematic Review and Analysis of Physicochemical Properties.Clinical pharmacokinetics · 2024Pooled it
- Population Pharmacokinetic Modeling of Standard- and High-Dose Rifampicin for Tuberculosis Preventive Therapy in the 2R2 Randomized Controlled Trial.The Journal of infectious diseases · 2026Trial
- Twice-Daily Dosing of Dolutegravir in Infants on Rifampicin Treatment: A Pharmacokinetic Substudy of the EMPIRICAL Trial.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Trial
- Altered Pharmacokinetics and Delayed Sputum Conversion in Tuberculosis Patients Co-Infected With HIV.Tropical medicine & international health : TM & IH · 2026Observational
- Regimen-Specific Population Pharmacokinetics of Isoniazid with and Without Rifamycin: A Bayesian Modeling Analysis of 6H, 3HR, and 3H2P2 Regimens.Pharmaceutics · 2026Article
- Tailoring Prevention and Control Strategies for Childhood Tuberculosis: From a Global Analysis of Burden Trends and Inequalities Across Three Age Groups (1990-2021) to Prevention and Control Strategies.Tropical medicine and infectious disease · 2026Article
- Is Short Therapy an Appropriate Regimen for Children and Young Adolescents with Drug-Susceptible Tuberculosis?Pharmaceuticals (Basel, Switzerland) · 2026Review
- Population pharmacokinetics of pyrazinamide and ethambutol in children with tuberculosis with or without HIV.Antimicrobial agents and chemotherapy · 2026Article
- Therapeutic Drug Monitoring for Improving Tuberculosis Treatment Outcomes: A Scoping Review of Clinical Studies.Clinical pharmacokinetics · 2026Article
- Analysis of factors influencing plasma concentrations of anti-TB drugs in pediatric TB patients.BMC infectious diseases · 2025Article
- Pharmacokinetic Analysis of an Isoniazid Suspension Among Spanish Children Under 6 Years of Age.Antibiotics (Basel, Switzerland) · 2025Article
- Association Between Diabetes Mellitus-Tuberculosis and the Generation of Drug Resistance.Microorganisms · 2024Review
- Predictive Mortality of the Prognostic Nutritional Index Combined with APACHE II Score for Critically Ill Tuberculosis Patients.The American journal of tropical medicine and hygiene · 2024Article
- Precision Medicine Strategies to Improve Isoniazid Therapy in Patients with Tuberculosis.European journal of drug metabolism and pharmacokinetics · 2024Review
- Pharmacokinetics and pharmacodynamics of high-dose isoniazid for the treatment of rifampicin- or multidrug-resistant tuberculosis in Indonesia.The Journal of antimicrobial chemotherapy · 2024Observational
- Push forward LC-MS-based therapeutic drug monitoring and pharmacometabolomics for anti-tuberculosis precision dosing and comprehensive clinical management.Journal of pharmaceutical analysis · 2024Review
- Effect of HIV infection on plasma exposure to first-line TB drugs and target attainment in children.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2023Article
- First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia.Journal of the Pediatric Infectious Diseases Society · 2023Article
Corrections and comments
- Commented on by
Authors and funding
65 authors at 20 institutions in 18 countries.
Fajri GafarUniversity of Groningen, Groningen Research Institute of Pharmacy, Unit of PharmacoTherapy, -Epidemiology and -Economics, Groningen, The Netherlands f.gafar@rug.nl.ORCID 0000-0002-0084-9018
Roeland E WasmannUniversity of Cape Town, Department of Medicine, Division of Clinical Pharmacology, Cape Town, South Africa.
Helen M McIlleronUniversity of Cape Town, Department of Medicine, Division of Clinical Pharmacology, Cape Town, South Africa.
Rob E AarnoutseRadboud University Medical Center, Radboud Institute of Health Sciences, Department of Pharmacy, Nijmegen, The Netherlands.
H Simon SchaafStellenbosch University, Faculty of Medicine and Health Sciences, Department of Paediatrics and Child Health, Desmond Tutu Tuberculosis Centre, Tygerberg, South Africa.ORCID 0000-0001-5755-4133
Ben J MaraisThe Children's Hospital at Westmead, Sydney, Australia.ORCID 0000-0003-3404-2690
Dipti AgarwalRam Manohar Lohia Institute of Medical Sciences, Department of Paediatrics, Lucknow, India.
Sampson AntwiKomfo Anokye Teaching Hospital, Department of Child Health, Kumasi, Ghana.
Nguyen D BangPham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam.
Adrie BekkerStellenbosch University, Faculty of Medicine and Health Sciences, Department of Paediatrics and Child Health, Desmond Tutu Tuberculosis Centre, Tygerberg, South Africa.
David J BellNHS Greater Glasgow and Clyde, Infectious Diseases Unit, Glasgow, UK.
Chishala ChabalaUniversity of Cape Town, Department of Medicine, Division of Clinical Pharmacology, Cape Town, South Africa.ORCID 0000-0002-5551-5752
Louise ChooUniversity College London, Medical Research Council Clinical Trials Unit, London, UK.
Geraint R DaviesMalawi Liverpool Wellcome Clinical Research Programme, Clinical Department, Blantyre, Malawi.
Jeremy N DayOxford University Clinical Research Unit, Ho Chi Minh City, Vietnam.
Rajeshwar DayalSarojini Naidu Medical College, Department of Pediatrics, Agra, India.
Paolo DentiUniversity of Cape Town, Department of Medicine, Division of Clinical Pharmacology, Cape Town, South Africa.
Peter R DonaldStellenbosch University, Faculty of Medicine and Health Sciences, Department of Paediatrics and Child Health, Desmond Tutu Tuberculosis Centre, Tygerberg, South Africa.
Ephrem EngidaworkAddis Ababa University, College of Health Sciences, School of Pharmacy, Department of Pharmacology and Clinical Pharmacy, Addis Ababa, Ethiopia.ORCID 0000-0002-9931-6421
Anthony J Garcia-PratsStellenbosch University, Faculty of Medicine and Health Sciences, Department of Paediatrics and Child Health, Desmond Tutu Tuberculosis Centre, Tygerberg, South Africa.ORCID 0000-0002-9280-1950
Diana GibbUniversity College London, Medical Research Council Clinical Trials Unit, London, UK.ORCID 0000-0002-9738-5490
Stephen M GrahamUniversity of Melbourne, Department of Paediatrics and Murdoch Children's Research Institute, Royal Children's Hospital, Melbourne, Australia.ORCID 0000-0003-3525-2294
Anneke C HesselingStellenbosch University, Faculty of Medicine and Health Sciences, Department of Paediatrics and Child Health, Desmond Tutu Tuberculosis Centre, Tygerberg, South Africa.
Scott K HeysellUniversity of Virginia, Division of Infectious Diseases and International Health, Charlottesville, VA, USA.
Misgana I IdrisUniversity of Alabama at Birmingham, Department of Biology, Birmingham, AL, USA.
Sushil K KabraAll India Institute of Medical Sciences, Departments of Pediatrics, New Delhi, India.
Aarti KinikarByramjee Jeejeebhoy Government Medical College - Johns Hopkins University Clinical Research Site, Pune, India.
Agibothu K Hemanth KumarIndian Council of Medical Research, National Institute for Research in Tuberculosis, Chennai, India.
Awewura KwaraUniversity of Florida, Emerging Pathogens Institute, College of Medicine, Gainesville, FL, USA.
Rakesh LodhaAll India Institute of Medical Sciences, Departments of Pediatrics, New Delhi, India.
Cecile Magis-EscurraRadboud University Medical Center - TB Expert Centre, Nijmegen, The Netherlands.
Nilza MartinezInstituto Nacional de Enfermedades Respiratorias y Del Ambiente, Asunción, Paraguay.
Binu S MathewChristian Medical College and Hospital, Department of Pharmacology and Clinical Pharmacology, Vellore, India.
Vidya MaveByramjee Jeejeebhoy Government Medical College - Johns Hopkins University Clinical Research Site, Pune, India.
Estomih MdumaHaydom Lutheran Hospital, Center for Global Health Research, Haydom, Tanzania.ORCID 0000-0002-9401-3982
Rachel Mlotha-MitoleQueen Elizabeth Central Hospital, Department of Paediatrics, Blantyre, Malawi.
Stellah G MpagamaKibong'oto Infectious Diseases Hospital, Sanya Juu, Tanzania.
Aparna MukherjeeAll India Institute of Medical Sciences, Departments of Pediatrics, New Delhi, India.
Heda M NataprawiraUniversitas Padjadjaran, Hasan Sadikin Hospital, Faculty of Medicine, Department of Child Health, Division of Paediatric Respirology, Bandung, Indonesia.
Charles A PeloquinUniversity of Florida College of Pharmacy, Gainesville, FL, USA.
Thomas PouplinMahidol University, Faculty of Tropical Medicine, Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand.
Geetha RamachandranIndian Council of Medical Research, National Institute for Research in Tuberculosis, Chennai, India.
Jaya RanjalkarChristian Medical College and Hospital, Department of Pharmacology and Clinical Pharmacology, Vellore, India.
Vandana RoyMaulana Azad Medical College, Department of Pharmacology, New Delhi, India.
Rovina RuslamiUniversitas Padjadjaran, Faculty of Medicine, Department of Biomedical Sciences, Division of Pharmacology and Therapy, Bandung, Indonesia.
Ira ShahBai Jerbai Wadia Hospital for Children, Department of Pediatric Infectious Diseases, Pediatric TB Clinic, Mumbai, India.
Yatish SinghSarojini Naidu Medical College, Department of Pediatrics, Agra, India.
Marieke G G SturkenboomUniversity of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.
Elin M SvenssonRadboud University Medical Center, Radboud Institute of Health Sciences, Department of Pharmacy, Nijmegen, The Netherlands.
Soumya SwaminathanIndian Council of Medical Research, National Institute for Research in Tuberculosis, Chennai, India.
Urmila ThatteSeth Gordhandas Sunderdas Medical College and King Edward Memorial Hospital, Department of Clinical Pharmacology, Mumbai, India.
Stephanie TheeCharité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Berlin, Germany.ORCID 0000-0001-9090-7869
Tania A ThomasUniversity of Virginia, Division of Infectious Diseases and International Health, Charlottesville, VA, USA.
Tjokosela TikisoUniversity of Cape Town, Department of Medicine, Division of Clinical Pharmacology, Cape Town, South Africa.
Daan J TouwUniversity of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.
Anna TurkovaUniversity College London, Medical Research Council Clinical Trials Unit, London, UK.
Thirumurthy VelpandianAll India Institute of Medical Sciences, Ocular Pharmacology and Pharmacy Division, Dr R.P. Centre, New Delhi, India.
Lilly M VerhagenRadboud University Medical Center, Radboud Center for Infectious Diseases, Laboratory of Medical Immunology, Section of Pediatric Infectious Diseases, Nijmegen, The Netherlands.
Jana L WincklerStellenbosch University, Faculty of Medicine and Health Sciences, Department of Paediatrics and Child Health, Desmond Tutu Tuberculosis Centre, Tygerberg, South Africa.
Hongmei YangUniversity of Rochester, School of Medicine and Dentistry, Department of Biostatistics and Computational Biology, Rochester, NY, USA.
Vycke YunivitaUniversitas Padjadjaran, Faculty of Medicine, Department of Biomedical Sciences, Division of Pharmacology and Therapy, Bandung, Indonesia.
Katja TaxisUniversity of Groningen, Groningen Research Institute of Pharmacy, Unit of PharmacoTherapy, -Epidemiology and -Economics, Groningen, The Netherlands.
Jasper StevensUniversity of Groningen, University Medical Center Groningen, Department of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.
Jan-Willem C AlffenaarThe University of Sydney, Sydney Institute for Infectious Diseases, Sydney, Australia.ORCID 0000-0001-6703-0288
Global Collaborative Group for Meta-Analysis of Paediatric Individual Patient Data in Pharmacokinetics of Anti-TB Drugs
Desmond Tutu HIV Foundation · ZAUniversity of Cape Town · ZAAll India Institute of Medical Sciences · INIndian Council of Medical Research · INRadboud University Nijmegen · NLUniversity College London · GBUniversity Medical Center Groningen · NLChristian Medical College, Vellore · INJohns Hopkins University · USPadjadjaran University · IDSarojini Naidu Medical College · INThe University of Sydney · AUUniversity of Florida · USUniversity of Groningen · NLUniversity of Virginia · USAddis Ababa University · ETBai Jerbai Wadia Hospital for Children · INDr. Hasan Sadikin General Hospital · IDDr. Ram Manohar Lohia Institute of Medical Sciences · INHaydom Lutheran Hospital · TZ
Funding
ZOPOLRESTAT PHARMACOKINETICS IN DIABETICS WITH VARYING RENAL FUNCTIONM01RR000051 · NCRR · UNIVERSITY OF COLORADO DENVER · PI CAMPBELL, THOMAS A · 1985 to 2008
$52.6MUrine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and AdultsR01AI137080 · NIAID · UNIVERSITY OF VIRGINIA · PI Scott K Heysell, Leonid Kagan · 2018 to 2026
$6.3MPharmacokinetics of Anti-tuberculosis and Antiretroviral Drugs in ChildrenR01HD071779 · NICHD · UNIVERSITY OF FLORIDA · PI KWARA, AWEWURA JACOB · 2012 to 2022
$6.0MDiagnostics and Pharmacotherapy for Severe Forms of TBU01AI115594 · NIAID · UNIVERSITY OF VIRGINIA · PI HEYSELL, SCOTT K, HOUPT, ERIC R · 2015 to 2019
$3.0MOptimal dosing of 1st line antituberculosis and antiretroviral drugs in childrenR01HD069175 · NICHD · UNIVERSITY OF CAPE TOWN · PI MCILLERON, HELEN · 2011 to 2018
$1.8MImproving Pediatric Tb Diagnosis and Management in TanzaniaK23AI097197 · NIAID · UNIVERSITY OF VIRGINIA · PI THOMAS, TANIA A · 2012 to 2016
$645kPHARMACOKINETICS OF ANTITUBERCULOSIS DRUGSR01AI037845 · NIAID · NATIONAL JEWISH HEALTH · PI PELOQUIN, CHARLES ARTHUR · 1995 to 1999
–Medical Research Council MC_UU_00004/04Medical Research Council MC_UU_12023/26Medical Research Council MC_UU_12023/27Medical Research Council MR/L004445/1NCRR NIH HHS M01 RR000051NIAID NIH HHS K23 AI097197NIAID NIH HHS R01 AI037845NIAID NIH HHS R01 AI137080NIAID NIH HHS U01 AI115594NICHD NIH HHS R01 HD069175NICHD NIH HHS R01 HD071779Wellcome TrustWorld Health Organization 001
Abstract
backgroundSuboptimal exposure to antituberculosis (anti-TB) drugs has been associated with unfavourable treatment outcomes. We aimed to investigate estimates and determinants of first-line anti-TB drug pharmacokinetics in children and adolescents at a global level.
methodsWe systematically searched MEDLINE, Embase and Web of Science (1990-2021) for pharmacokinetic studies of first-line anti-TB drugs in children and adolescents. Individual patient data were obtained from authors of eligible studies. Summary estimates of total/extrapolated area under the plasma concentration-time curve from 0 to 24 h post-dose (AUC
resultsOf 55 eligible studies, individual patient data were available for 39 (71%), including 1628 participants from 12 countries. Geometric means of steady-state AUC
conclusionsThis study provides the most comprehensive estimates of plasma exposures to first-line anti-TB drugs in children and adolescents. Key determinants of drug exposures were identified. These may be relevant for population-specific dose adjustment or individualised therapeutic drug monitoring.
Indexed as
Antitubercular AgentsIsoniazidAdolescentChildChild, PreschoolEthambutolHumansPyrazinamideRifampinAntitubercular AgentsEthambutolIsoniazidPyrazinamideRifampin
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.